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EE  Entrapment/Encapsulation Efficiency (amount of drug 
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Blindness and visual impairment affect millions of people worldwide and have a very important 
impact on the patients quality of life. Proteins and peptides represent nowadays an important 
therapeutic tools for the treatment of ocular diseases but, despite their potential, have 
significant limitations, as  and their administration of protein-based pharmaceuticals represents 
a real challenge. AdditionalyMoreover, drug administration administration of ocular 
medications to the eye is a difficult task, due to the peculiar structure of this organ and the 
presence of numerous barriers protecting the eye internal tissuesinner structure. 
Nanoencapsulation of peptides and proteins presents a number of advantages for their ocular 
delivery could, in principle, be of help since it can protect the drug from metabolic activity, 
control and sustain the release and increase drug bioavailability after topical and or intravitreal 
administration. In fact, nanoparticulate formulations are contributing to overcome ocular 
barriers, such as the corneal or the blood-retinal barrier, improve the residence time in the eye, 
increase local drug level, reduce the drug dosage and showing improved performance when 
compared to conventional formulations, 
 
Besides, proteins can also be usedhave also been proposed  as excipients for the preparation 
of nanocarriers intended for ophthalmic administration, since they are highly biocompatible,  
and biodegradable and easily amenable to modifications for themodified to attachment oflink 
surface ligands. 
The present review focuses the attention on the use of   proteins sin in ocular drug delivery 
nanotechnology:: their dual role as both  therapeutics and carriers has been critically 




1 Ocular drug delivery 
Blindness and visual impairment affect millions of people worldwide and have a very 
important impact on the quality of life. The main causes in middle-income and 
industrialized countries are represented by glaucoma, age-related macular degeneration 
(AMD) and diabetic retinopathy. These pathologies are prevalent in the elderly and in 
diabetic patients and, because of aging population and lifestyle change, the prevalence of 
these diseases is expected to rise significantly. Beside these, other pathologies with 
inflammatory, infective, genetic or degenerative causes involve different ocular structures.  
In the past years, the introduction of new pharmacological strategies involving proteins 
(such as anti-vascular endothelial growth factor – VEGF - monoclonal antibodies – mAb -) 
has significantly changed the clinical outcome of some of these diseases, such as wet 
AMD. The continuous improvement of understanding the molecular basis of the 
pathologies will probably increase the number of possible drug candidates in the next 
years. 
Despite the new available molecules, drug administration to the eye remains a difficult 
task, due to the peculiar structure of this organ and the presence of numerous barriers, 
static and dynamic, protecting the internal tissues. 
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1.1 Ocular anatomy 
 
Figure 1. Schematic representation of human eye (with permission from [1]). 
 
Figure 1 illustrates the structure of the human eye [1]. The eye bulb has three concentric 
tunics, one external, fibrous layer comprising the cornea and sclera; one intermediate 
vascular tunic comprising the iris, ciliary body, and choroid; and one internal, nervous tunic 
or retina. Additionally, the eye can be roughly divided into two segments, separated by the 
lens: the anterior segment (conjunctiva, cornea, anterior and posterior chambers 
containing aqueous humor, iris and lens) and the posterior segment (vitreous body, retina, 
choroid and posterior sclera). Anterior and posterior chambers are filled with the aqueous 
humor, while the vitreous cavity is filled with a gel-like fluid called vitreous humor. The 
conjunctiva is a transparent mucous membrane that covers the inner surface of the eyelids 
and the surface of the anterior sclera; it is continuous with the cornea and the junctional 
region is called limbus. The epithelium of the cornea and of the conjunctiva are covered by 
mucins (secreted mucins – both gel forming and small soluble - and cell surface-
associated mucins) playing a lubricant and protective role and contributing to the 
hydrophilic character of wet-surfaced epithelia [2, 3]. 
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For the treatment of anterior segment diseases and for the management of glaucoma, the 
application of eye drops, gels or ointments in the conjunctival fornix and/or on the ocular 
surface, is the simplest and generally preferred administration route. However, this route is 
characterised by low compliance (often due to the high administration frequency required) 
and low drug bioavailability (generally lower than 5%). The latter is due to the short 
residence time of the formulation on the ocular surface and to the low permeability of the 
cornea. The cornea is an avascular tissue consisting of a collagenous layer (stroma) 
enclosed by an anterior epithelium and a posterior endothelium. The epithelium, with tight 
junctions in its superficial layers, represents the main barrier toward the penetration of 
drugs. 
The posterior segment of the eye is not accessible to drugs applied topically on the cornea 
or in the conjunctival cul-de-sac; on the other hand the efficacy of systemic administration 
is hindered by the presence of the blood-retinal barrier (BRB) and limited by possible 
systemic toxicity. BRB is composed by two distinct barriers, located in different regions: 
the outer BRB is located in the retinal pigment epithelium (RPE), while the inner BRB is 
located in the endothelium of retinal microvasculature. 
For these reasons, the intravitreal injection (i.e. direct injection of the drug in the vitreous 
body) is, at present, the most efficient option for drug administration to the retina. 
However, due to the serious side effects, other, alternative and less invasive 
administration routes are in use or under investigation: trans-scleral (comprising 
subconjunctival, sub-Tenon, peribulbar, posterior juxta-scleral and retrobulbar injections), 
intra-scleral and subchoroidal delivery are among them. Using these routes the drug is not 
directly available to the retina, but must diffuse across the underlying tissues, overcoming 
static (sclera, choroid, Bruch’s membrane, RPE) and dynamic barriers, such as blood and 
lymphatic flux and choroidal circulation. 
It is worth mentioning that the integrity, structure and efficiency the different barriers 
involved in ocular drug delivery can change as a function of two important factors: aging 
and disease. Since aging is the most important risk factor for several eye diseases, the 
changes produced by the two causes tend to overlap. Disease-induced barrier weakening 
or disruption had been shown to influence deeply drug distribution. When the epithelial 
barrier of the cornea is compromised by the presence of corneal neovascularization (NV), 
for example, the topical application of a mAb can be effective in the treatment of anterior 
segment diseases [5]. Concerning the posterior segment, as an example, celecoxib 
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accumulation in retina and vitreous, following periocular administration, was higher in 
diabetic than in healthy rats, because of the disruption of BRB produced by diabetes [6]. 
2 Nanoparticles and eye 
Nanomedicines are medicinal products with at least one component at nano-scale size. 
Until a few years ago the size was the only classification criterion and the nano range was 
defined as the interval 1-100 nm. Presently, in the EMA website, nanotechnology is 
defined as “the use of tiny structures - less than 1,000 nanometres across - that are 
designed to have specific properties”, significantly widening the size range and 
emphasizing the role of nanometric dimension on the clinical advantages (i.e. specific 
organ/tissue distribution), more than the sole effect on chemical and physical properties 
(generally observed for materials with size below 100 nm) [7]. Similarly, the FDA has 
recently released a Guidance for Industry where the nanotechnology definition is extended 
to materials or end products “engineered to exhibit properties or phenomena, including 
physical or chemical properties or biological effects, that are attributable to its 
dimension(s), even if these dimensions fall outside the nanoscale range, up to one 
micrometer (1,000 nm)” [8]. 
Numerous and diverse are the contributions given (or that could be given in the future) by 
the nanotechnologies to the treatment of eye diseases [9]: sensors for biophysical 
measurement (such as wireless contact lenses for IOP - intra ocular pressure - 
measurement), biosensors for diagnostic and theragnostics [10], prosthetics (i.e. sight 
restoring therapy by retinal cell stimulation), regenerative nanomedicine [11] and 
nanocarriers, such as nanoparticles, liposomes and other vesicular carriers, micelles and 
dendrimers, for the delivery of drugs, peptides and genes. The use of nanocarriers in 
ocular drug delivery can address some of the the main unmet medical needs, such as the 
low bioavailability of antibiotics, anti-inflammatory and antiviral drugs, the treatment of 
retinal and corneal NV, degenerative diseases, hereditary retinal disorders and tumors. 
Additionally, refractive cornea surgery, healing process in the eye, gene therapy, 
regenerative medicine (growth factors delivery) could highly benefit from nanocarriers. 
The possible advantages of using nanocarriers are due to the special physical and/or 
chemical properties produced by size reduction, that differ from those at macroscopic 
scale. In particular, in the case of nanocarriers for pharmaceutical use the most important 
property is the increased surface area-to-volume ratio. This leads to an increasing 
dominance of the behaviour of atoms on the surface of a particle, affecting all the surface 
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phenomena and the interactions with other materials, such as those present in the 
biological environment in which the particle finds itself after administration. In this 
perspective, it is clear that size, shape, surface charge, surface coating and 
functionalization, as well as the nature of the constituent material, highly influence 
nanocarriers performance and biocompatibility. These characteristics can often be 
controlled and tuned thanks to parameters variation in the preparation procedures. 
In general, NPs have been proposed as carriers to protect the encapsulated drug from 
degradation, control drug release, increase residence time on the ocular surface, facilitate 
the transport of drugs into cells and finally increase drug bioavailability. Additionally, due to 
the very small dimensions, NPs can be administered through any of the routes previously 
mentioned. 
However, the usefulness of this carriers in ocular drug delivery is not “universal” and the 
benefits depend upon several factors, such as the ocular pathology involved (the different 
localization inside the ocular bulb but also the target that can be both extra and intra 
cellular), the administration route and the characteristics of the drug (in particular its 
potency, its physico-chemical characteristics and its stability in a biological environment). 
Furthermore, some issues about NPs for ocular delivery must be highlighted. When 
considering the ocular anatomy, for instance, it is evident that there are important 
limitations on the volumes that can be administered. For example, maximum one drop (50 
µl) is considered suitable for topical application, 20-100 µl for intravitreal injection, 500 µl 
for subconjunctival injection, 35 µl for intra-scleral injection and 35-100 µl for 
suprachoroidal delivery [12, 13]. It follows that, in order to administer a significant amount 
of drugs, NPs should have an high drug loading (not easy to achieve) and/or be highly 
concentrated, especially in the case of drugs administered at high doses. NPs are not 
always physically stable and can aggregate when present at high concentration; as a 
consequence, despite the immune privilege of the eye, inflammatory and/or 
immunostimolatory events could occur. The issues related to nanomaterial toxicity are a 
hot topic, that is presently the subject of numerous paper and public discussions. 
Reflection papers can be found in the website of regulatory agencies, but very few data 
are available on the specific toxicity on ocular tissues. NP toxicity is related not only to the 
polymer used (for instance, PLGA - Poly(Lacti-co-Glicolic) Acid - is already used for the 
intravitreal implant Ozurdex® and demonstrated good tolerability), but also to the size that 
can promote cell-uptake, with possible accumulation inside the retinal cells and damage of 




3 Administration routes 
3.1 Topical administration 
Topical administration is used when the target is the conjunctiva, the cornea or the anterior 
and posterior chambers. The limitations of this delivery route, i.e. short formulation 
residence time, eye irritation, undesirable systemic absorption, low corneal permeability, 
could, in principle, be overcome by using particulate carriers. Because of the small size, in 
fact, NPs dispersed in an appropriate liquid can be applied just like eye drops without the 
sticky feeling or blurring of vision caused by ointments. Additionally, they do not cause 
scratching, nor foreign body sensation; they control drug delivery, reducing administration 
frequency, and protect the drug from chemical or enzymatic degradation meanwhile 
reducing the irritating potential on the ocular surface. Finally, nanoparticulate systems give 
the opportunity to administer compounds with poor water solubility using an aqueous 
vehicle. 
The main advantage that can be achieved using nanoparticulate carriers is an improved 
drug bioavailability in the anterior chamber, generally due to increased residence time and, 
in some cases, enhanced trans-corneal permeability. 
The increase in residence time in the cul-de-sac and on the ocular surface can be 
obtained by using mucoadhesive excipients. The presence of mucoadhesive polymers 
allows NPs to adhere to the pre-corneal or conjunctival mucus layer by non-covalent 
bonds and to remain on the ocular surface for as long as mucin is present. This can 
ultimately lead to a reduction of the frequency of drug administration and thus increase 
patient compliance. A detailed review on this topic has been recently published [15]. When 
the constituting polymer is not mucoadhesive, NPs can be superficially coated with 
mucoadhesive polymers such as chitosan, hyaluronate or alginate [16]. 
The improved drug bioavailability reported using nanocarriers can also be ascribed to an 
enhanced trans-corneal transport, due to NPs permeation. This phenomenon has been 
reported with different polymers and/or coatings and has been ascribed to different 
phenomena: opening of tight junction in the corneal and conjunctival epithelia, so as to 
improve the transport across the paracellular pathway, NPs endocytosis, cellular lysis due 
to NP degradation products [17-19]. 
Apparently, the possibility for NP to cross the epithelial layers depends upon NP size and 
surface properties such as charge, composition (hydrophilicity/hydrophobicity) and 
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coating/functionalization. One of the most studied polymers is chitosan, a natural 
polysaccharide characterized by biocompatibility, biodegradability, mucoadhesion, and the 
ability to transiently enhance the permeability of mucosal barriers [20]. At the same time, 
also NPs unable to permeate the cornea have been reported: a recent paper from Mun et 
al., for instance, demonstrated on an ex vivo bovine eye model that neither thiolated nor 
PEGylated (0.75 and 5 kDa) silica NPs with a mean diameter between 20 and 70 nm could 
penetrate the epithelium [21]. 
In the literature several recent reviews are present on the use of nanoparticulate carriers 
for anterior segment diseases. Cholkar [22] analyses in particular the results related to 
anti-inflammatory drugs, while a recent review from Gonzalez et al. provide an overview of 
the possible use of nanotechnology in corneal NV [23]. Kim [24] and Pita-Thomas [25] 
describe the results obtained and the potential implications for the glaucoma treatment. 
 
3.2 Intravenous administration 
Intravenously administered NPs have been studied to target and treat posterior segment 
diseases, based on the assumption that they can pass through the BRB. Sakai [26] 
demonstrated, in an experimental uveoretinitis model in rats, that betamethasone loaded 
in PLGA NPs accumulated in the retina after intravenous injection and was more effective 
than when injected alone. Kim et al. found that intravenously administered gold 
nanoparticles can cross the BRB depending on particle size. In particular, 100 nm NPs 
were not found in the retina, while 20 nm NPs passed the BRB and were detected in all 
retina layers [27]. The possibility to cross the BRB is often related to the presence of 
ocular diseases. For instance, PLGA NPs loaded with recombinant Flt23k intraceptor 
plasmid for gene therapy were injected intravenously in a rodent model of laser-induced 
choroidal neovascularization (CNV): NPs accumulate in the neovascular eye, but not in the 
control eye, indicating that drug ocular bioavailability following intravenous injections 
depends upon the integrity of BRB. These NPs were also functionalised with the tripeptide 
arg-gly-asp (RGD) that can bind integrin receptors, and/or with transferrin that can bind 
transferrin receptor on the retinal cells surface. In both cases the surface functionalization 




3.3 Intravitreal injection 
The main goal of the intravitreal injection is to deposit the drug in close contact with the 
target site (retina/RPE/retinal blood vessels/vitreous). Despite its efficacy, this route of 
administration has significant drawbacks and risks, such as bleeding, pain, infection, IOP 
increase and retinal detachment. Additionally, for the treatment of chronic diseases such 
as AMD, monthly intraocular injections are needed, with a corresponding increase in the 
risk of side effects. Another limitation of this dosage regimen is an initial very high drug 
concentration in the vitreous that can be responsible for important side effect, in particular 
in the case of corticosteroids. 
In order to reduce these problems, intravitreal implants have been proposed [29, 30]. In 
this perspective, NPs can be of help since they can be easily injected with a conventional 
needle and form a reservoir inside the vitreous; due to the small size they should not 
interfere with the vision (or maybe limit the blurring of vision compared to microparticles); 
they protect the drug from the environment, increasing the drug half-life in the vitreous and 
can control the release of the drug thus avoiding peak and valleys in the vitreous 
concentration (even though they are less efficient in controlling drug release compared to 
microparticles). In this way they could also reduce the amount of drug that needs to be 
administered and possibly the volume to be injected (thus reducing IOP increase). 
An additional property attributed to nanoparticulate carriers is the ability to cross cell 
membranes. The first evidence that polymeric NPs can enter the cells is dated 1977 when 
Patrick Couvreur studied cell internalization of 200 nm nanocapsules [31]. Presently, many 
papers have demonstrated NPs uptake into cells also in the case of ocular delivery, even 
though the mechanisms involved are not always known. Mechanisms elucidated till now 
are endocytosis, clathrin and caveolin mediated endocytosis [32] and endocytosis 
mediated by transferrin/deslorelin receptors with NPs functionalized with transferrin and 
deslorelin [33, 34]. The NP cell-uptake can be particularly useful in the case of intracellular 
diseases and gene therapy, for which NPs have also demonstrated to enhance the 
transfection efficacy [35]. 
The fate of NPs injected in the vitreous depends upon the size and the NP surface 
characteristics, since these properties mediate the interaction with the vitreous humor 
components, i.e. collagen fibrils and glycosaminoglycans [36]. Bourges et al. in 2003 
injected PLA (polylactic acid) NPs loaded with fluorescent probes and found a quick trans-
retinal passage and an accumulation in RPE cells up to 4 month after injection. Neither the 
size (140 vs 310 nm) nor the zeta potential (-60 mV vs -6 mV) seems to influence the 
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distribution [37]. The importance of surface chemistry on intravitreal movement was 
evidenced by different authors [38-40]. Kim found that cationic nanoparticles diffuse more 
slowly in the vitreous than anionic NPs (probably because of a ionic interaction with 
hyaluronan) and that the positive charge hinders movement more than the size. This data 
was also confirmed using self assembled polymeric NPs in a murine model: strongly 
cationic PEI (polyethylenimine) nanoparticles interacted tightly with the vitreous matrix, 
while cationic glyco chitosan NPs penetrated the vitreous and reached the inner limiting 
membrane but could not cross it. On the contrary anionic NPs of hyaluronic acid and 
human serum albumin (HSA) showed the ability to penetrate across the whole retina and 
accumulate in the RPE [39]. 
The importance of both size (100-1000 nm) and surface chemistry was also investigated 
ex vivo using polystyrene (PS) amine-modified (cationic PS-NH2), carboxy-modified 
(anionic PS-COOH) and PEG coated (not charged, PS-PEG) nanoparticles [41]. A 
summary of the results obtained is illustrated in Figure 2 and highlights: (i) steric hindrance 
for 1000 nm particles; (ii) electrostatic hindrance for positively charged NPs; (iii) 
hydrophobic hindrance for concentrated negatively charged NPs; (iv) free diffusion for non-
adhesive (PEG coated) NPs smaller than 1000 nm. These results, obtained ex vivo using 
real-time multiple particle tracking (MPT), can be of great help in the future design of NPs 





Figure 2. Schematic illustration of the effect of size and surface characteristics on NPs 
transport in the vitreous. Hydrophobic, electrostatic and steric effects can hinder particle 
transport in vitreous meshwork. Particles with size ≥ 1000 nm were immobilized due to 
steric hindrance; dilute PS-COOH NP (≤ 200 nm) diffused freely within vitreous, while 
concentrated PS-COOH NP aggregated because of hydrophobic interactions. 500 nm PS-
COOH NP was greatly hindered due to both hydrophobic and steric effects; PS-NH2 NP 
aggregated because of electrostatic interactions with the negatively charged vitreous; non-
adhesive PS-PEG NP diffuse freely within vitreous if their size was no larger than 500 nm. 
From [41] with permission. 
3.4 Trans-scleral, intra-scleral, suprachoroidal administration 
These new administration routes have been proposed as an alternative to intravitreal 
injection to reach the posterior segment of the eye without the side effects and risks of 
direct injection. In the trans-scleral delivery, the drug must cross the whole sclera to reach 
the underlying tissues; this happens when the drug is applied in the conjunctival fornix, but 
also in case of subconjunctival, sub-Tenon, peribulbar, posterior juxta-scleral and 
retrobulbar injections. NPs can be used in these administration routes mainly to create a 
drug reservoir in order to control and sustain the delivery of drug for long periods, thus 
reducing administration frequency. NPs should in this case be retained as long as possible 
at the injection site so as to deliver all the loaded dose However, apparently, microparticles 
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(MPs) seems to be a better solution, because of the higher drug loading, lower burst effect 
and better control of drug release [42]. Additionally, MPs are characterized by a slower 
clearance in the periocular space, compared to NPs. The fate of nanoparticles (20 and 200 
nm and 2 µm carboxylate polystyrene NPs, negatively charged) has been investigated 
after periocular administration and the 20 nm NPs were rapidly cleared by blood and 
lymphatic circulation, while 200 nm and 2 µm particles was still found in the periocular 
tissues after 60 days [43]. The fast clearance of small NPs was also recently confirmed by 
Feng et al. using pRNA NPs 10 nm in size [44], while a significantly longer retention was 
demonstrated by latanoprost-loaded NPs of 80 nm that sustained drug level in the 
aqueous humor for at least 6 days [45]. 
In the intra-scleral delivery, a drug reservoir is injected in the sclera thickness using an 
hollow microneedle: Jiang at al. demonstrated in vitro the relatively easy injection of 
solutions and nanoparticles (PLA, 280 nm) in human sclera, while MPs (latex, 1 µm) could 
not be delivered in the same way, due to the blockage by the fibrous microstructure of 
scleral tissue [46]. Despite the interesting results obtained, there is a limited space 
accessible for fluid infusion into the sclera (max 10-35 µl) and this limits the amount of 
drug that can be delivered. An alternative approach, that could in principle allow the 
delivery of higher volumes, is represented by the suprachoroidal injection, that deposes 
the drug between the sclera and the choroid. A solution injected in the suprachoroidal 
space spreads circumferentially around the eye. Data obtained ex vivo and in vivo with 
different animal models demonstrate the possibility of easily injecting particles with 
diameters between 20 nm and 10 µm. These particles (non-biodegradable), administered 
in vivo to New Zeland white rabbits, remained in the suprachoroidal space for at least 2 
months without any sign of clearance [12, 47]. 
4 Nanoencapsulation of therapeutic proteins 
Proteins represent nowadays very important therapeutic tools. The total global market for 
protein-based therapies is growing very fast, with mAbs dominating. At present, more than 
240 mAb and 120 proteins are in clinical trials or under development for the treatment of 
cancer, immune disorders, infections, and degenerative diseases [48]. Proteins are used 
also for the treatment of several eye diseases. Together with the well known bevacizumab, 
ranibizumab and aflibercept, anti-VEGF agents for neovascularization-related eye 
diseases, other proteins are in use or under development [49]. Table 1 presents the 
therapeutic proteins in use or under investigation for the treatment of eye diseases. 
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Despite their potential, proteins have important limitations as therapeutics and their 
administration represents a real challenge, for several reasons [50]: 
(i) permeability across endothelial and epithelial structure is very low. For instance, 
they show very poor ability to penetrate the blood-brain barrier and the blood-
retina barrier; additionally, the intracellular targeting is very difficult and this is 
the reason why, at present, protein therapeutics are mainly limited to cell surface 
or extracellular targets; 
(ii) they can have stability problem (aggregation) and/or can be degraded by 
enzymes naturally present in the body; 
(iii) all protein therapeutics are potentially immunogenic in patients; 
(iv) they are generally very expensive. 
Nanoencapsulation of peptides and proteins could be of help for solving some of the 
previously mentioned issues. NPs can protect the drug from metabolic activity that is 
present in ocular tissues [51] and in the vitreous body [52] thus prolonging their half-life, 
and can control and sustain the release of the active. These actions will also reflect in a 
reduction of the required dose, with a possible positive impact on costs. Finally, NPs can 
promote drug retention on ocular surface (mucoadhesion), penetration across epithelia 
and cell internalization. 
However, the complications related to protein nanoencapsulation cannot be neglected. 
The problems are strictly linked to the encapsulation method used, nevertheless, some 
general consideration can be made. First of all the method chosen must preserve protein 
structure and activity; this is a very delicate aspect, also considering the extensive use of 
heat and/or organic solvents in NPs production. Sometimes, to preserve drug activity, the 
therapeutic protein is loaded after the nanoparticle/liposome production procedure. Due to 
the high drug cost it is very important to optimize the production procedure so as to 
increase as much as possible the encapsulation efficiency. In general, it is known that the 
encapsulation efficiency (EE) is inversely related to the size of the particles (the procedure 
and the polymer being the same, EE is generally higher for MPs compared to NPs). In 
analogy, by reducing the size of the particles, also the control of the release is reduced, 
with the appearance of an important burst effect. Together with EE, also the drug loading 
(LC) is of the outermost importance, in particular in the case of highly dosed protein, so as 
to reduce as much as possible the amount of excipient to be used. This aspect is 
significant, also considering the very small volumes that can be delivered in the case of 
ocular administration (see section 2). All these consideration justify the reason why at the 
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moment no protein-loaded nanoparticles are present on the market, also in the case of 
ophthalmic application.  
In the next paragraphs, a review of scientific works describing ocular delivery of NPs 
containing therapeutic or model proteins is presented. The data have also been 
summarised in Table 2. It is worth noting that all the paper found on this subject are very 
recent and demonstrate a growing interest on this subject driven by the recent discovery of 
the molecular basis of some ocular pathologies, by the increased possibility of protein 
production thanks to the DNA recombinant techniques and by the undeniable relevance 
and impact that sight problems have in our society. 
4.1 Anti-angiogenic drugs 
Bevacizumab (AvastinTM) is a recombinant humanized mAb of 149 kDa. Bevacizumab 
blocks the angiogenic process by binding strongly to human vascular endothelial growth 
factor. Despite the lack of approval for ophthalmic therapy, it is currently used, by repeated 
intravitreal injections, for the treatment of retinal NV. It is also reported to be efficacious to 
treat corneal NV, administered as eye drops. The use of NPs can represent a convenient 
strategy for bevacizumab delivery and several examples can be found in the literature. 
Liposomes loaded with bevacizumab were prepared following the dehydratation-
rehydratation method, using phospholipid and cholesterol in molar ratio 1:1. Bevacizumab 
was added to blank multilamellar liposomes and the mixture was freeze-dryied: the 
encapsulation efficiency was 45% and bevacizumab remained stable during the 
preparation procedure. The intravitreal injection of bevacizumab-loaded liposomes in 
rabbits in vivo, allowed to achieve a higher drug concentration-time curve and a slower 
clearance compared to the antibody solution [53]. 
The preparation of PLGA NPs using the emulsification/solvent evaporation technique is 
reported by different authors [54-58]. Pan has described bevacizumab containing NPs with 
an average size of 819 nm and a LC of 2.2%. Inside NPs, which were evaluated for the 
treatment of CNV in a rat model, the mAb retained its activity [55]. Concerning the 
antibody stability during the preparation procedure, Varshochian reported the positive 
effect exerted by albumin, which, at the same time, can be of help also in the control of 
drug release [56]. Hao and colleagues have prepared bevacizumab-PLGA NPs, which, 
unlike previous examples, were intended for trans-scleral delivery [57]. 
In order to avoid one of the more important drawbacks of NPs, i.e. the limited control of 
drug release and the presence of a burst effect, a system composed of nanoparticles 
entrapped in porous MPs was prepared and evaluated. In particular, bevacizumab-coated 
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PLA NPs were encapsulated into porosyfing PLGA microparticles using supercritical 
carbon dioxide [59]. Supercritical carbon dioxide enabled the rapid expansion of PLGA, 
while produced no effect on crystalline PLA: the final entrapment of PLA NPs into PLGA 
microparticles was confirmed by SEM images (Figure 3). 
 
 
Figure 3. Bevacizumab-loaded PLA NPs in porous PLGA MPs. Panel A. Scanning electron 
microscopy image (5000 X). Panel B. bevacizumab concentration in rat ocular tissues 2 
months after intravitreal injection of bevacizumab solution and bevacizumab-NPinPMP. In 
case of NPs in MPs, bevacizumab was not detected in conjunctiva, cornea and aqueous 
humor; in case of the solution, bevacizumab was not detected in any of the ocular tissues 




Despite the supercritical treatment, bevacizumab maintained its activity. When the MPs 
were injected in a rat model, the antibody was constantly released in vitreous over a period 
of 2 months (Figure 3); the authors hypothesized that PLA NPs behaved as plugs by 
blocking PLGA pores, thus delaying bevacizumab release. 
Recently, bevacizumab was loaded in annexin-associated liposomes intended for 
application on the ocular surface, but with the final aim to target the retina [60]. 100 nm 
unilamellar liposomes, negatively charged (approximately -5 mV) were prepared by the 
lipid film hydratation method and the resulted EE was about 22-25%. The presence of a 
functionalizing protein as annexin A5 on the liposome surface enhanced the transport 
across epithelial barriers, allowing bevacizumab to reach the posterior chamber in in vivo 
experiments on rats and rabbits (see also section 6). 
Widely used in therapy for treating retinal diseases is also ranibizumab. Ranibizumab 
(Lucentis®; 48 kDa) is the Fab fragment of a humanized mAb approved for intravitreal 
injection. Ranibizumab exerts its anti-angiogenic activity by binding to three VEGF 
isoforms, i.e. VEFG165, VEGF121 and VEGF110 [61]. Being one third in weight if compared 
to bevacizumab, ranibizumab is a good candidate for the development of NPs. An 
example of ranibizumab NPs was reported by Patel and colleagues, who successfully 
prepared PLGA NPs loading a ranibizumab-dextran sulphate complex, obtained via 
hydrophobic ion pairing (HIP) complexation (i.e. a complex based on the formation of an 
hydrophobic reversible interaction between macromolecules showing opposite charges). 
After complex formation, the NPs, 150 nm in size, were prepared by nanoprecipitation and 
had a maximum entrapment of approx. 85% [62]. HIP complexation has been previously 
described by the same research group, who developed PLGA NPs loaded with BSA [63] 
or lysozime [64], chosen as model proteins, in order to set-up the preparation of NPs able 
to guarantee not only the sustained delivery of the protein loaded, but also to preserve its 
therapeutic activity. 
In 2011 FDA approved the use of aflibercept, a fully human recombinant fusion protein 
that exerts an anti-angiogenic activity by “entrapping” VEGF and thus preventing the 
interaction with VEGFR. From a clinical point of view, aflibercept has demonstrated a 
comparable efficacy to ranibizumab [65]; however, to date no data concerning aflibercept 
loading NPs are available. 
Two recent examples of new anti-angiogenic peptides are C16Y, a 1.6 kDa integrin-
antagonist peptide with hydrophilic properties, active in blocking integrins involved in NV 
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process, and SP6001, a serpin-derived peptide negatively charged. C16Y was 
successfully encapsulated in polylactic acid/polylactic acid-polyethylene oxide (PLA/PLA-
PEO) NPs (approximately 300 nm, negatively charged -38 mV), in order to improve the 
peptide intravitreal half-life as well as retinal penetration. In vivo studies performed using a 
model of NV in rats, demonstrated the higher efficacy of C16Y-loaded NPs compared to 
the peptide solution [66]. For SP6001 intravitreal delivery, poly(beta-amino ester) (PBAE), 
a cationic polymer, was used to obtain self-assembled polymer-peptide NPs (119 nm), that 
were than encapsulated inside PLGA microparticles (approx 10 µm) to extend peptide 
release [67]. In vitro, the system showed approximately zero order release of SP6001 for 
more than 6 months; in vivo, after injection in mice with CNV, angiogenesis decreased for 
at least 3 months: a better result than for peptide alone, which controlled the pathologic 
condition for less than one month. 
 
4.2 Neuroprotective factors 
Basic fibroblast growth factor (bFGF) is a neuroprotective agent involved in the prevention 
of photoreceptors degeneration. In order to protect the peptide and avoid complications 
associated to the direct injection of naked bFGF inside the ocular bulb, the protein was 
loaded on gelatin NPs. bFGF was incorporated by dropping a drug solution on freeze-dried 
gelatin NPs [68]. The intravitreally injected NPs (approx. 600 nm in size) were retained 
inside RPE and retina for at least 8 weeks after administration, allowing a sustained 






Figure 4. Confocal images of the retina of RCS rat 6 (A) and 8 (B) weeks after injection of 
rhodamine-labeled bFGF-NPs. NPs are present in the inner plexiform layer (IPL), and in 
the outer nuclear layer (ONL) at 6 weeks. At 8 weeks after injection, the NPs were in the 
inner nuclear layer (INL), ONL, and RPE apical surface. Arrowheads: NPs. Scale bar, 50 
μm. From [68] with permission (to be obtained). 
 
A small signal peptide, made only of serine, threonine and tyrosine, was conjugated to 
low molecular weight chitosan NPs, and proposed to treat macular degeneration thanks to 
its ability to act as a transduction agent inside RPE cells [69]. To prevent RPE cells 
apoptosis, recently Wang and colleagues proposed the use of a mini-peptide, made of 20 
amino acids, derived from the heat shock protein αβ-crystallin and having chaperone 
properties [70]. Despite its neuroprotective activity, the small size makes the peptide highly 
exposed to intraocular degradation, with consequent very low viability. In order to minimize 
this aspect, an innovative bioengineering approach involving NPs was adopted. The mini-
peptide was fused to an elastin-like polypeptide (40 kDa), used as carrier protein. This 
fusion-construct, expressed in E. coli using the DNA recombinant technique, self-assembly 
into small NPs following a temperature-dependent process. The resulted NPs, about 30 
nm in size, were tested in human RPE cell culture, in which an oxidative stress was 
induced. The anti-apoptotic activity exerted by mini-peptide was preserved; furthermore, 
cell internalization, probably via clathrin-mediated endocytosis, took place. 
 
4.3 Anti-inflammatory agents 
Among anti-inflammatory agents, the introduction of anti TNF-alpha in ophthalmology for 
the treatment of uveitis and retinal diseases represents a recent fact and several studies 
are ongoing in order to demonstrate their efficacy and safety [71]. Efficacy and safety have 
been assessed for adalimumab and infliximab, two IgG mAbs, while the soluble TNF 
receptor fusion protein etanercept is no longer a candidate because of its tendency to 
worsen uveitis [72]. Among others anti TNF-α, certolizumab and golimumab have 
recently been approved for systemic use but they have not yet been tested in ocular 
inflammation affections [73]. 
Since the systemic administration of TNF-α inhibitors can result in several side effects 
(chiefly, an increase tendency to develop infectious diseases) [71], an alternative 
treatment based on local application is preferred. 
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At the present time no literature data are available concerning ophthalmic NPs containing 
infliximab; on the contrary, the development of adalimumab NPs has been reported. 
Adalimumab (HumiraTM) is a 148 kDa recombinant human IgG mAb, approved for the 
treatment of several rheumatic diseases (among which, rheumatoid arthritis and Crohn’s 
disease) by means of subcutaneous injection [74]. It binds both soluble and membrane 
forms of TNF-α, a pleiotropic cytokine involved in the development and maintenance of 
inflammatory processes having an autoimmune origin. In ophthalmology, adalimumab has 
displayed its ability in controlling and preventing anterior and refractory uveitis as a 
consequence of subcutaneous administration [75]. Romero et al. have developed 
PolyElectrolyte Multilayers (PEMs) PLGA) NPs to control adalimumab delivery [76]. 
PolyElectrolytes used were alginate (negatively charged) and polylysine, which has a 
polycation nature. Blank PLGA NPs were prepared using the emulsion/solvent evaporation 
method and were then covered by using the layer-by-layer (LbL) technique. The positively 
charged antibody was added to alginate, in order to obtain a negatively charged complex 
(zeta potential approx. -25 mV). Then, polylysine and antibody/alginate complex were 
alternatively layer-by-layer deposited onto NPs up to 11 or 25 levels, in strictly controlled 
conditions of pH and ionic strength. Since the outer layer was always polylysine, the zeta 
potential of the final PEMs NPs corresponded to +13 mV. In vitro adalimumab release in 
PBS followed a first order kinetic after an early burst effect. After 1 and 5 days, the 
percentages of antibody released were respectively of 50% and 60-70%. Even if the 
described NPs have been proposed for local delivery, they have not been yet tested 
specifically for ocular application; however the preliminary data suggest their potentiality in 
ophthalmologic field, also for the delivery of different proteins. 
Vasoactive intestinal peptide (VIP) is an endogenous ocular peptide, consisting of 28 
amino acid residues, with recognized immunomodulatory properties. Peptide-loaded 
liposomes (between 300 and 600 nm in size) were prepared by thin layer hydration and 
loaded by lyophilization-rehydration. These carriers were developed in order to protect VIP 
against degradation, when intravitreally injected in rats with endotoxin-induced uveitis [77]. 
The study demonstrated the effectiveness of liposomes in controlling VIP release as well 
as their ability in protecting the peptide for 14 days. In this case the presence of the 
nanocarrier is essential to ensure the stability of VIP, which, when directly injected inside 




4.4 Model proteins 
Bovine serum albumin (BSA) is universally recognized as model protein. BSA is a 67 kDa 
hydrophilic and globular shape protein, with a hydrodynamic radius of 36 Å; the deep 
characterization, the high versatility, the reproducible behaviour, the good stability in 
solution, as well as the relatively low cost, justify its wide use as model compound in the 
pharmaceutical research field. BSA is therefore often chosen as reference protein in 
several type of NPs intended for mucosal application. For instance, hyaluronic 
acid/chitosan NPs, obtained by the ionic gelification technique [78] have been proposed for 
topical application, because the excipients are mucoadhesive, biocompatible and 
biodegradable. Xu et al. prepared PEGilated NPs PLGA-PEG NPs, via emulsification 
method, in order to obtain mucus penetrating properties [79]. 
Recently, fluorescently labelled BSA was also loaded on silk fibroin NPs [80] intended for 
the treatment of retinal diseases. The NPs are intended for trans-scleral delivery and their 
penetration should be enhanced by ultrasound (US) application. NPs were prepared 
following the anti-solvent precipitation method. A silk fibroin solution (2.5% w/v) was 
injected in acetone: immediately, silk fibroin NPs were formed and precipitated. After a 
purification by centrifugation, NPs were add a FITC-BSA solution and mixed. 
Glutaraldehyde solution was added dropwise and cross-linking reaction took place in 8 
hours. Silk fibroin NPs, both blank and BSA-loaded, were about 200 nm in size. The EE 
resulted 76%. Passive trans-scleral diffusion of BSA loaded NPs resulted 8 time higher 
than BSA solution. As expected, the penetration efficiency of NPs showed a further 
increase when associated to US: almost 14-fold higher with respect to albumin solution 
and fibroin NPs demonstrated their stability in presence of US [80]. The work is a very 
good example of how the combination between NPs and a physical enhancer can lead to 
targets not achievable until few decades ago. 
5 Carrier proteins 
Proteins can be used as excipients for the preparation of NPs and have demonstrated to 
be suitable for the delivery of both small and high molecular weight active ingredients. 
Protein nanocarriers allow to preserve drug activity, to sustain drug release and enable the 
targeting to specific substrates; in fact, proteins are easily amenable to modifications to 
allow the attachment of targeting ligands. Proteins, being in most cases of natural origin, 
show high biocompatibility and biodegradability, are well characterized and may be 
considered safe enough, at least from a general point of view. The natural origin can also 
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be a drawback because of the possible immunogenicity (particularly due to aggregation), 
the high variability and sometimes the need to remove from the starting material all the 
contaminants that may produce toxicity in human [81] as, for example, the possible 
presence of transmissible spongiform encephalopathy vectors in bovine gelatin [82]. 
Despite these limitations, the use of protein as excipients for NPs preparation have 
interesting perspectives. It is worth mentioning, for instance, that one of the more 
successful examples of nanoparticle formulation on the market is made of albumin 
(Abraxane®). 
Nanoparticles have been prepared using both water-soluble (serum albumin) and water-
insoluble proteins (such as zein and gliadin). The next paragraphs review the use of 
proteins as nanocarriers for ocular drug delivery. 
Fibroin is a high MW protein, composed of a 25 kDa light chain and a 325 kDa heavy 
chain, joined by a disulfide bond; the two chains are non-covalently connected to P25, a 
25 kDa glycoprotein [83]. Fibroin is extracted from cocoons of Bombyx mori (mulberry 
silkworm) and purified from sericin, a protein coating single fibroin filaments. Silk fibroin 
has been used to prepare ocular NPs via anti-solvent precipitation method [80]. In vivo 
mucoadhesion tests performed on rabbit demonstrated the ability of the silk fibroin NPs to 
quickly adhere on sclera surface, while, as previously reported in the present paper, in 
vitro permeation studies confirmed the diffusion enhancement of BSA loaded in fibroin 
NPs, particularly when US were associate, with respect to BSA solution. 
Being BSA highly versatile, it is used as a model of therapeutic protein (see section 4.4), 
but also as a carrier protein. Especially thanks to their biocompatibility and the 
biodegradability, many examples of albumin NPs for ocular use can be found in the 
literature. Most of them are intended for topical application and are loaded with small drugs 
such as antiglaucoma agent pilocarpine [84], anti-inflammatory compounds, such as 
hydrocortisone [85], aspirin [86], and meloxicam [87], antiviral drugs like acyclovir [88]. 
Zimmer and collaborators used a slightly modified desolvation method to prepare 
hydrocortisone-loaded albumin NPs, starting from a micellar solution of the lipophilic drug. 
The NPs obtained, having a size ranging between 100 and 300 nm, displayed an EE up to 
70% and demonstrated their efficacy in both in vitro and in vivo studies [85]. Following the 
same method, also albumin NPs loaded with the hydrophilic pilocarpine were prepared 
and characterized [84]. In this case, the use of NPs instead of the solution has increase 
1.5-1.9-times the miotic effect, with a consequent significant reduction of the IOP. 
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Desolvation method was used by Noomwang to prepare bovine albumin NPs of spherical 
shape and average size of 130 nm [88]. Acyclovir was successfully loaded with 20% of EE 
and 1% of LC. 
Using the desolvation based coacervation technique Das [86] prepared aspirin-loaded 
albumin NPs having a size of 65 nm, with low polydispersity index, and a positive zeta 
potential (+25 mV). The average drug entrapment was 80% and in vitro studies showed 
the ability of NPs to release the NSAID for as long as 3 days, without any burst effect. 
Furthermore, DLS analysis demonstrated the stability of the lyophilized NPs for at least 6 
months. Based on their experimental data, the authors hypothesized the use of the above-
mentioned NPs, intended for topical administration, also for the treatment of posterior 
segment affections. 
 
Thanks to the optimal tolerability, albumin represents also a suitable carrier for NPs 
intended to be administered intravitreally. NPs injected inside the ocular bulb enable a 
sustained release of the active inside the vitreal chamber, with consequent reduction in the 
number of injections needed. The hydrophilic drug ganciclovir, antiviral treatment of 
cytomegalovirus retinitis, was firstly loaded in albumin particles by El-Samaligy, who 
obtained spherical particles having an average particle size of 1.2 μm [89]. Afterwards, 
other several successful attempts were done in order to optimize the nanoparticulate 
formulation, by using the coacervation method and loading ganciclovir not only inside NPs, 
but also on their surface [90]: the entrapment efficiency resulted 40% for loaded NPs and 
20% for those with the drug adsorbed on the superficial layer. The presence of ganciclovir 
on NPs surface resulted in a more effective antiviral activity since, once NPs are 
internalized by cells, the drug is released in a more rapid way [91]. 
As antiviral activity against human cytomegalovirus can be explicated also by antisense 
oligonucleotide, both phosphodiester and phosphorotioate oligonucleotides were either 
adsorbed on the surface or incorporated inside albumin NPs [92]. The entrapment 
efficiency was approx. 74% for phosphodiester while 59% in the case of phoshorotioate, 
reflecting the different affinity of the two oligonucleotides for albumin. The average size 
(250 nm) as well as the charge (-22 mV) were independent from the loading method and 
oligonucleotide type; [92]. Even if the NP preparation procedure preserved oligonucleotide 
hybridization capability, the simple adsorption onto NPs surface does not efficiently protect 
the oligonucleotide against enzymatic degradation. However, BSA NPs improved the 
internalization of oligonucleotides inside cells. 
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In order to deliver more effectively and to protect genetic material intended for ophthalmic 
treatment, some authors described the use of HSA NPs as non-viral vector for both 
intravitreal [38, 93] and intracorneal [94] administration. HSA NPs enabled the sustained 
release of the gene loaded and were rapidly uptaken from cells via receptor-mediated 
endocytosis. Furthermore, they demonstrated complete lack in cytotoxicity [93]. Human 
serum albumin NPs showed their safety also with regard to corneal keratocytes [94]. 
Gelatin is a composite of purified protein fractions derived from porcine and bovine 
collagen, available as type A gelatin, obtained by partial acid hydrolysis, type B gelatin, 
produced by partial alkaline hydrolysis, or a mixture of the two [95]. Gelatin is largely used 
in pharmaceutical technology as gelling agent, film-forming agent, viscosity enhancer and 
different grades of gelatin, with different particle size, molecular weight and other 
properties, are commercially available [95]. As nanocarrier, gelatine offers, among 
otherpolymers and biopolymers, a peculiar characteristic, which consists in the 
polyampholyte nature, due to the presence of cationic and anionic group together with 
hydrophobic groups [96]. 
Thanks to the high biocompatibility shown, several examples of gelatin NPs intended for 
ophthalmic use can be found in the literature. Gelatin allows the preparation of both 
positive and negative NPs, with smooth surface and spherical shape [97], to be 
administered either topically [97, 98] or intra-vitreally [68] and loaded with small molecules 
[98] as well as with high molecular weight compounds [68]. In order to increase ocular 
bioavailability of pilocarpine HCl and hydrocortisone, two drugs with different solubility, 
they were encapsulated in gelatin NPs via desolvation method [98]. NPs encapsulating 
pilocarpine showed that the type of gelatine as well as pH conditions did not affect the 
particle size and charges, that resulted slightly negative; on the contrary, hydrocortisone 
NPs showed different zeta potential, as a consequence of use of different gelatine type, 
even if the charge was negative in any case. 
Since the ocular surface is negatively charged, because of the presence of sialic acid 
residues in the mucus, some authors suggested that cationic NPs may better interact 
and/or penetrate cornea and conjunctiva than the anionic ones [97, 99]. For this reason, 
cationic gelatin NPs were prepared and loaded with a plasmid designed to encode human 
MUC5AC [100]. MUC5AC is a mucin protein that plays a role in the homeostasis of 
lacrimal fluid and is thus reduced in dry eye syndrome. NPs were prepared by ionic 
gelation technique starting from cationized gelatin; plasmid and an anionic polymer 
(chondroitin sulphate or dextran sulphate) were added to the cationic gelatine solution in 
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the presence of tripolyphosphate. NPs obtained were characterized by a small size (less 
than 150 nm) and a positive surface charge (between +20 mV and +30 mV). The 
administration of associated plasmid NPs to rabbit cornea was followed by a an increase 
of the MUC5AC levels detected inside the precorneal tear film. 
Gelatin NPs have been also proposed for intravitreal administration. In fact, freeze-dried 
gelatin NPs, obtained by UV cross-linking, were used as nanocarrier for basic fibroblast 
growth factor (bFGF) [68] (see also section 4.2). An electrostatic interaction occurred 
between negative gelatin and positive bFGF: the growth factor was released in vivo from 
the complex as a consequence of environmental changes, such as an increase of ionic 
strength and enzymatic degradation of gelatin. The study clearly demonstrated the ability 
of gelatin NPs to preserve bFGF from degradation, and, at the same time, to guarantee 
the anti-apoptotic effect thanks to a sustained release targeted to photoreceptors. 
In the ophthalmic field, a recent example of nanoplatform based on elastin like 
polypeptide (ELP) was described for the intravitreal administration of a chaperone, as 
previously discussed in the present review [70]. Elastin like polypeptides are biopolymers 
derived from hydrophobic domain of tropoelastin, the soluble precursor of elastin. As well 
as tropoelastin, ELPs are soluble at low temperature, but, as a consequence of thermal 
raising, the solubility progressively decreases and self-assembly takes place [101]. Even if 
ELPs are commonly known to be termoresponsive, they may be designed to react to other 
physical change, such as pH variation [102]. Several characteristics can be controlled, 
among which MW is surely the most important, especially when ELPs are intended for the 
preparation of platforms, or even nanoplatforms, for drug delivery. The use of recombinant 
silk-elastin like protein for NPs production was also reported [103], even if not yet used for 
ocular formulations. 
6 Peptides and proteins as functionalizing and coating agents 
Finally, it is worth mentioning the role of proteins and peptides as active coating agents, 
that can enhance the cell adhesion and promote cell uptake. The idea, very simple but at 
the same time highly effective, consists in the conjugation of NPs with peptides or proteins, 
whose receptors are expressed on ocular tissues. Some examples are reported in the 
literature: among them, the conjugation of deslorelin and transferrin to polystirene NPs 
[33]. Deslorelin is a 1.3 kDa synthetic nonapeptide LHRH agonist, while transferrin is a 
glycoprotein having a MW of 80 kDa; they were chosen to functionalize NPs surface 
because of the expression of their receptors on both corneal epithelium and conjunctiva. In 
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fact, the presence of specific receptors on ocular tissues justified the increase of the 
transport of conjugated NPs of approx. 70% across cornea (Figure 5) and 50% through 
conjunctiva in an ex vivo bovine model, if compared to conventional NPs. 
 
Figure 5. Ex vivo accumulation of coated and uncoated fluorescent nanoparticles (85-100 
nm) in bovine cornea. Panels A-D: confocal images showing the uptake of nanoparticles in 
bovine cornea epithelium after 4 hours application using  a modified Ussing chamber. A. 
blank tissue, B. uncoated NPs; C deslorelin-NP; D. transferrin-NPs. Panels E-F: 
Nanoparticles content in the corneal tissues and acqueous humor 5 and 60 minutes after 
instillation in an ex-vivo bovine eye model (with permission from [33]).to be obtained 
 
Furthermore, confocal studies demonstrated the ability of deslorelin/transferrin NPs to be 
uptaken by epithelium unmodified, as well as the NPs accumulation in the stroma, with the 
formation of a reservoir [33]. Recently, another protein was selected as active coating of 
liposomes intended for corneal administration. Annexin A5 is a calcium-dependent 
phospholipid binding protein, having a MW of 36 kDa. Thanks to its ability to interact with 
cell and biological membrane, annexin A5-associated liposomes were prepared in order to 
promote their transport across the corneal barrier [60]. The presence of annexin enhanced 
the delivery of topically applied bevacizumab-loaded liposomes to the posterior segment of 
both rat and rabbit eyes in vivo. This result, that authors ascribed to the ability of annexin 
in increasing the contact time as well as in enhancing transcytosis across epithelium, is a 
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an example of how the simple use of a protein as functionalizing coating agent can lead to 
switch from an invasive approach to a well-tolerated one. 
A peptide active coating was also suggested to help the targeting of an anti-VEGF agent 
for the therapy of CNV, after intravenous injection of NPs: in fact, Luo et al. reported the 
use of the cell adhesion motif RGD tripeptide (arginine-glycine-aspartic acid) [104]. In this 
case the intravenous administration route was proposed as a valid alternative to the 
intravitreal injection of anti-VEGF, the latter procedure being poorly tolerated and 
sometimes injurious (see also section 3.2). 
Finally, proteins can be useful in NPs preparation to promote physical stability and control 
the drug release rate. Some authors have suggested the use of albumin as coating agent 
of meloxicam nanocrystals (approx. average particle size 100 nm) intended for the 
treatment of postcataract endophthalmitis [87]. Furthermore, bovine serum albumin, as 
well as human serum albumin, showed stabilizing effects on therapeutic proteins when the 
NPs procedure involved an emulsification method [56]. 
7 Future perspectives 
7.1 Potential drug candidates 
The number of therapeutic proteins proposed for the treatment of ocular diseases is 
constantly growing, thanks to the considerable contribution of biotechnology (Table 1). 
Among these, the newly developed therapeutic proteins are briefly detailed below. 
Recombinant MP0112 is an anti-VEGF, belonging to DARPins, a new generation of 
designed low MW therapeutic proteins made by repeated ankyrin domains, that recently 
demonstrated its safety and bioactivity following intravitreal injection in the treatment of 
diabetic macular edema [105] and exudative AMD [106]. 
Plasminogen kringle 5 (K5) is an 80 amino-acids natural peptide having proved anti-
angiogenic properties, effective in prevention and block of retinal NV. After intravitreal 
administration, despite its effectiveness, it shows a very short half-life [107]. To minimize 
this low bioavailability, an expression plasmid of K5 was included in PLGA/chitosan NPs 
and then administered via injection in rats in vivo, with consequent K5 expression in all the 
layers of the retina [108]. Due to the high potential of the peptide, the possibility to prepare 
K5 loaded NPs should be take into account. 
ESBA105 is a 26.3 kDa single chain variable region antibody fragment (scFv) direct 
against TNF-α. ESBA105 reached high concentration levels inside the anterior and 
posterior ocular tissues when topically applied in ex vivo and in vivo experiments 
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performed on rabbits eye, thanks to both trans-corneal and trans-scleral permeation routes 
[109]. Recently, ESBA105 was successfully applied as eye drops in an in vivo study 
carried on human volunteers, reaching therapeutic levels inside anterior chamber, even if 
penetration inside the vitreous was low [110]. Even if no penetration enhancers are 
required [109, 110], this scFv antibody should be considered a suitable candidate for NPs 
not to improve the permeation, which is quite high, rather to better control the amount 
permeated and to increase ESBA105 half-life inside ocular chambers, which is only 25 
hours inside the vitreous [109]. 
The neuroprotectant agent GDNF (glial cell line-derived neurotrophic factor) exerts a 
neuroprotective effect by increasing the retinal ganglion cells survival. Since PLGA 
microspheres intended for intravitreal delivery were developed and successfully 
administered to rats in vivo [111], this positive result may suggest a similar desirable effect 
using NPs. 
Recombinant human Hsp70 (rhHsp70) is a 72 kDa chaperone that has recently 
demonstrated its ability in prevent RPE degeneration, when studied in vitro on cellular 
lines [112]. In view of in vivo studies, the authors hypothesize that the formulation of the 
protein as NPs will provide a sustained release of the chaperone after intravitreal injection. 
 
7.2 Carriers 
Among animal proteins, casein and β-lactoglobulin from milk appear very promising 
carriers for drug delivery. Caseins constitute a family of four phosphoproteins (ranging in 
weight between 19 and 25 kDa), which appear very rich in proline residues, heat stable 
and amphiphilic, that can lead to formation of self-assembly micellar structures in aqueous 
solutions [113]. Casein has been already approved as excipient in tablet preparation and, 
as a consequence of its versatile physico-chemical properties, extensively used for the 
preparation of hydrogels, floating beads, microparticles [113] and more recently for 
nanoparticles [114-116]. Similarly, β-lactoglobulin, MW 18.4 kDa, is widely used in both 
pharmaceutical and nutraceutical fields and several examples of β-lactoglobulin NPs were 
reported [117-119]. Even if generally described as emergent nanocarriers, neither casein, 
nor β-lactoglobulin NPs has been yet proposed for ophthalmic administration, but certainly 
they deserve to be further investigated for this purpose. 
Anyway, from a general point of view, some examples of ophthalmic NPs based on animal 
proteins are available and albumin is the main example, as previously seen in the present 
paper;  the same thing can not be said for plant protein. Although generally used for 
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preparation of nanocarriers, plant proteins are still missing in ocular formulation even if, 
several candidates are available: among others legumin, gliadin, soybean and zein. 
Legumin is a 360 kDa protein contained in peas. Proposed as carrier for NPs, thanks to 
the evidence that, by using the pH coacervation method, NPs of 250 nm in average 
diameter may be obtained [120]. Another possible source of carrier protein for NPs 
preparation is wheat gluten, from which the insoluble protein gliadin can be isolated; 
literature reports gliadin NPs intended for oral drug delivery [121]. 
Soybean is a source of proteins, the so-called soy protein isolated (SPI), mainly consisting 
of two globular proteins, glycinin (360 kDa) and β-conglycinin (180 kDa). Since they show 
both hydrophilic and lipophylic properties, they are, at least in principle, suitable for active 
compounds having different properties [122]. As often noticeable for biopolymers, being 
SPI very versatile, it was proposed their use for realizing films, as devices for controlling 
the release of drugs [123], and preparing NPs [124], but also as nanosuspension 
stabilizers for poorly water-soluble compounds, in analogy with β-lactoglobulin [119]. 
Nevertheless, to date no examples in ophthalmic delivery are available. 
Finally, the relative small zein, a 38 kDa prolamine protein, contained in the seeds of 
maize, showing marked hydrophobic properties. Zein is commonly used in pharmaceutical 
technology field as tablet coating agent, tablet sealer, as well as wet granulation binder 
[95] and it has been studied as protein carrier starting from few years ago [125-127], also 
in association with another protein, i.e. β-lactoglobulin [118]. However, no one has yet 
reported the use of zein-based NPs in ocular drug delivery. Even if no data for ocular 
application are available, in perspective, zein use could be take into account, being 
mucoadhesive, having a self-assembling nature and the ability to form both solid core and 
hollow NPs; furthermore, the possibility of loading biomacromolecules, such as proteins 
and peptides, and the protective effect exerted against enzymes have been already 






Table 1 Therapeutic proteins in use or under investigation in ophthalmology 
 
PROTEIN MW (kDa) TARGET/DISEASE REF. 
antiAnti-angiogenic factors 
aflibercept 115 wet AMD [65] 
anti-HER2 rhuMAb 148 NV [49] 
bevacizumab 149 NV [129] 
C16Y 1.6 CNV [66] 
K5 (plasminogen kringle 5) 14 NV [107] 
MP0112 (DARPins, ankyrin repeat 
proteins) 
15-18 DME, AMD [105, 106] 
PEDF 50 CNV [49] 
ranibizumab 48 AMD [61] 
rituximab 145 intraocular lymphoma [49] 
sFlt-1 110 CNV [49] 
SP6001 (serpin-derived peptide) 1.3 NV [130] 
neuroprotective Neuroprotective factors 
aFGF (also called FGF-1) 17 photoreceptor degeneration [49] 
αβ –crystallin derived small 
peptide 
2.4 AMD [70] 
BDNF 28-37 photoreceptor degeneration [49] 
bFGF (also called FGF-2) 17-23 photoreceptor degeneration [68] 
CNTF 23 glaucoma [49] 
GDNF 20 glaucoma [111] 
NGF 26 glaucoma [49] 
rhHSP70 chaperone (recombinant 
hHsp70) 
72 RPE degeneration [112] 
small signal tripeptide 0.4 AMD [69] 
antiAnti-inflammatory agents 
adalimumab 148 uveitis [74] 
infliximab 149 uveitis, CNV [49] 
ESBA105 (single chain Ab fragment) 26 AMD [110, 131] 
VIP 3.3 uveitis [77] 
model Model proteins 
BSA 67 - - 
cytochrome c 12 - - 
HSA 66 - - 
lysozyme 14 - - 





Table 2. List of therapeutic and model proteins loaded in NPs for ophthalmic use 
 
PROTEIN MW (kDa) 
CARRIER* 
Written in 
italics, in the 




ROUTE REF. YEAR 
anti-angiogenic factors 
bevacizumab 149 
liposome - NV intravitreal injection [53] 2009 
PLGA 230 NV trans-scleral [57] 2009 
PLGA 819 NV intravitreal injection [55] 2011 
PLGA 200-1000 NV intravitreal injection [54] 2012 
PLGA 165-1631 NV intravitreal injection [56] 2013 
PLA NPs in 
PLGA MPs 
NPs 265 
MPs 11610 NV 
intravitreal 




100 NV trans-corneal [60] 2014 
PLGA 168-362 NV subconjunctival [58] 2014 
ranibizumab 48 PLGA 150 AMD intravitreal injection [62] 2012 
C16Y 1.6 PLA/PLA-PEO 300 CNV 
intravitreal 
injection [66] 2010 
SP6001 (serpin-




119 NV intravitreal injection [67] 2013 
neuroprotective factors 
bFGF (also 








injection [68] 2007 
small signal 
tripeptide 0.4 chitosan 200 AMD 
intravitreal 








29 AMD intravitreal injection [70] 2014 
anti-inflammatory agents 
adalimumab 148 PLGA/PLL - uveitis topical [76] 2013 






312-1360 - topical/transmucosal [78] 2008 
PLGA/PEG 160-218 - topical/transmucosal [79] 2013 
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